Structural implications of drug-resistant mutants of HIV-1 protease: High-resolution crystal structures of the mutant protease/substrate analogue complexes
Article first published online: 27 APR 2001
Copyright © 2001 Wiley-Liss, Inc.
Proteins: Structure, Function, and Bioinformatics
Volume 43, Issue 4, pages 455–464, 1 June 2001
How to Cite
Mahalingam, B., Louis, J. M., Hung, J., Harrison, R. W. and Weber, I. T. (2001), Structural implications of drug-resistant mutants of HIV-1 protease: High-resolution crystal structures of the mutant protease/substrate analogue complexes. Proteins, 43: 455–464. doi: 10.1002/prot.1057
- Issue published online: 27 APR 2001
- Article first published online: 27 APR 2001
- Manuscript Accepted: 2 FEB 2001
- Manuscript Received: 31 AUG 2000
- U.S. Public Health Service. Grant Numbers: AI41380, GM62920
- Intramural AIDS Targeted Antiviral Program of the Office of the Director of National Institutes of Health
Emergence of drug-resistant mutants of HIV-1 protease is an ongoing problem in the fight against AIDS. The mechanisms governing resistance are both complex and varied. We have determined crystal structures of HIV-1 protease mutants, D30N, K45I, N88D, and L90M complexed with peptide inhibitor analogues of CA–p2 and p2–NC cleavage sites in the Gag–pol precursor in order to study the structural mechanisms underlying resistance. The structures were determined at 1.55–1.9-Å resolution and compared with the wild-type structure. The conformational disorder seen for most of the hydrophobic side-chains around the inhibitor binding site indicates flexibility of binding. Eight water molecules are conserved in all 9 structures; their location suggests that they are important for catalysis as well as structural stability. Structural differences among the mutants were analyzed in relation to the observed changes in protease activity and stability. Mutant L90M shows steric contacts with the catalytic Asp25 that could destabilize the catalytic loop at the dimer interface, leading to its observed decreased dimer stability and activity. Mutant K45I reduces the mobility of the flap and the inhibitor and contributes to an enhancement in structural stability and activity. The side-chain variations at residue 30 relative to wild-type are the largest in D30N and the changes are consistent with the altered activity observed with peptide substrates. Polar interactions in D30N are maintained, in agreement with the observed urea sensitivity. The side-chains of D30N and N88D are linked through a water molecule suggesting correlated changes at the two sites, as seen with clinical inhibitors. Structural changes seen in N88D are small; however, water molecules that mediate interactions between Asn88 and Thr74/Thr31/Asp30 in other complexes are missing in N88D. Proteins 2001;43:455–464. © 2001 Wiley-Liss, Inc.